Phase III trial with allergen specific sublingual immunotherapy in birch allergic patients: Significant and clinical relevant reduction of the combined symptom and medication score

Authors
Category Primary study
ConferenceAllergy: European Journal of Allergy and Clinical Immunology
Year 2016
This article has no abstract
Epistemonikos ID: 6ee281554f9474ec3c68b98ca7686f07b499b98d
First added on: Apr 29, 2026